Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatology international Lin, C. W., Chen, Y. S., Lo, G. H., Wu, T. C., Yeh, J. H., Yeh, M. L., Dai, C. Y., Huang, J. F., Chuang, W. L., Roberts, L. n., Jun, D. W., Toyoda, H. n., Yasuda, S. n., Nguyen, M. H., Yu, M. L. 2021

Abstract

Patients with Barcelona Clinic Liver Cancer Stage C (BCLC-C) hepatocellular carcinoma (HCC) can be markedly heterogeneous with varying prognosis. This study aims to establish a new subclassification system for BCLC-C HCC to better predict overall survival (OS) and to tailor therapy.We retrospectively studied 1856 BCLC-C HCC patients between 2006 and 2017 from E-Da Hospital, Taiwan (n?=?622, training cohort), Kaohsiung Medical University Hospital, Taiwan (n?=?774, Taiwan validation cohort), and Stanford University Medical Center and Mayo Clinic (United States), Hanyang University Hospital (South Korea), and Ogaki Municipal Hospital (Japan) to make up the international validation cohort (n?=?460).In the training cohort, significant factors associated with OS were largest tumor size?=?10 cm, extrahepatic spread, macrovascular invasion, and Child-Pugh class, which provided the basis, together with aged?=?75 years, for the substaging, through C0 to C4, of BCLC-C HCC patients. The median OS for substages C0, C1, C2, C3, and C4 were 43.8 months (95% confidence interval [CI] 32.2-53.7), 20.6 months (CI 14.1-25.9), 11.5 months (CI 8.02-14.1), 5.7 months (CI 4.02-5.98), and 3.2 months (CI 2.41-3.59), respectively, (p?

View details for DOI 10.1007/s12072-021-10169-8

View details for PubMedID 34008091